This document relates to methods and materials for treating urinary calculi. For example, ureteral orifice devices and methods for using ureteral orifice devices to treat urinary calculi present within a mammal (e.g., a human) are provided.

A Coude catheter insures proper drainage and reduces tissue damage by using an alignment indication section having an open passageway positioned on a proximal end of the catheter.

A method for coupling a body conduit to tissue includes engaging an implant about an outer surface of a catheter. The implant receives a bioactive agent having tissue growth properties. The method involves inserting the catheter through the body conduit and into a tissue opening across a resected area, positioning the implant in the resected area, inflating a balloon to anchor the catheter within the tissue opening such that the implant bridges the body conduit and the tissue opening across the resected area, and maintaining the catheter and the implant in vivo to enable the bioactive agent to secure the implant in the resected area to permanently bridge the body conduit and the tissue opening.

Method and system for treating a patient using a compressible, pressure-attenuating device. According to one embodiment, the system is used to treat urinary tract disorders and comprises an access device, a delivery device, a pressure-attenuating device, and a removal device. The access device can be used to create a passageway to an anatomical structure, such as the patient's bladder. The delivery device can be inserted through the passageway created by the access device and can be used to deliver the pressure-attenuating device to the anatomical structure. The removal device can be inserted through the passageway created by the access device and can be used to view the bladder and/or to capture, to deflate and to remove the pressure-attenuating device.

Devices and methods for trimming a stent to a desired length with an outer tube and an inner tube having a distal end and a diameter configured to receive a portion of the stent in excess of the desired length. The inner tube may move within the outer tube and the distal end may include an end effector configured to trim the portion from the stent while the device and stent are within a patient.

A prosthesis comprising a water-dissolvable coating. A prosthesis for a lacrimal canaliculus comprising a swellable punctal plug with a proximal end and a distal end, with the plug comprising a water-dissolvable biocompatible coating on the distal and/or the proximal end. Materials and methods for making and using the same. A prosthesis for placement in or across natural or prosthetic lumens, ostia, ducts, sinus, or sphincters, the prosthesis comprising a coating. The prosthesis can further provide a depot for sustained drug delivery to tissue.

A tubular patch (3) made of PGA fabric, optionally containing within it a mesh tubular support in PGA/PLA, for implantation to replace one or more urethral and/or ureteral removed segments for use in tissue reconstruction of the removed segments for the treatment of diseases such as necrosis, stenosis, tumours, trauma, iatrogenic injuries and the like, or congenital malformations.

A device for use within a woman's urethra for obstructing urine outflow when the pressure in the woman's abdomen is at or above a threshold pressure level (IAP1). The device also allows urine outflow when the intra-abdominal pressure is below the threshold pressure level (IAP1). The device includes a flexible tube that is configured to be inserted into a urethra, wherein the tube defines a lumen that has inlet and outlet openings. The tube is configured to receive, conduct and discharge urine. The tube is further configured such that the lumen is at least partially obstructed when the pressure on the urethra surrounding the tube at least meets the threshold pressure (IAP1), and the lumen is more open when the pressure on the urethra surrounding the tube is at a level below a second, lower, threshold pressure (IAP2).

Provided is a ureteral stent (=50) including a bladder portion (=52) positioned in a bladder of a patient, a kidney portion (=54) positioned in a kidney and ureteral passageway of the patient, and one or more tethers (=56) coupling the bladder portion to the kidney portion. The ureteral stent allows urine to pass around a blockage, and allows a ureter orifice connecting the ureteral passageway to the bladder to move between a compressed state and an uncompressed state to prevent or minimize urinary reflux, flank pain, blood in the urine, etc., while allowing the bladder portion to move freely in the bladder to prevent the bladder portion from irritating the trigone muscle.

A urethral stent for arrangement in the urethra of a patient is disclosed. The ethereal stent includes a tubular body having first and second openings, retention elements connected to the tubular body at the first opening and to the tubular body at a distance from the first retention element, and a valve. The valve includes a valve seat formed by the first opening and a valve element that is pivotably connected to the tubular body and/or the valve seat. The valve is pivotable between a closed position and an open position to close and open the lumen, respectively. The valve is at least partly made of a ferromagnetic material and has an area which exceeds the area of the first opening. A bladder control assembly comprising the urethral stent is also disclosed.